Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 12/20 | 0.60 |
| ▸ | NSD2 | O96028 | 6/20 | 0.58 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.56 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748578 | 0.92 | EHMT2 (0.62) | EHMT2NSD2SSTR5HRH1KDM1A | |
| SCHEMBL1748561 | 0.91 | EHMT2 (0.61) | EHMT2NSD2SSTR5HRH1KDM1A | |
| SCHEMBL1748467 | 0.91 | EHMT2 (0.62) | EHMT2NSD2SSTR5KDM1ARCOR1 | |
| SCHEMBL1748283 | 0.88 | SSTR5 (0.57) | EHMT2NSD2SSTR5HRH1 | |
| SCHEMBL1748223 | 0.86 | SSTR5 (0.57) | EHMT2SSTR5HRH1 | |
| SCHEMBL1748367 | 0.85 | SSTR5 (0.68) | EHMT2NSD2SSTR5HRH1 | |
| SCHEMBL16521336 | 0.85 | EHMT2 (0.75) | EHMT2NSD2KDM1ARCOR1DNMT3A | |
| SCHEMBL1748479 | 0.84 | EHMT2 (0.58) | EHMT2NSD2KDM1ARCOR1DNMT3A | |
| SCHEMBL3782357 | 0.84 | SSTR5 (0.57) | EHMT2NSD2SSTR5HRH1KDM1A | |
| SCHEMBL15280229 | 0.84 | NSD2 (0.80) | EHMT2NSD2KDM1ARCOR1DNMT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2044054-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| WO-2008000692-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | EHMT2 4858/4885NSD2 3810/4885SSTR5 1/4885 |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | SSTR5, SSTR3, NPY5R | EHMT2 4858/4885NSD2 3810/4885SSTR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.